• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: inhibitors

  • New Targets Bring Promise For Lung Cancer Therapy
    • in General Medicine
    • — 17 Mar, 2008

    New Targets Bring Promise For Lung Cancer Therapy

    Egbert Smit
    Egbert Smit

    EGBERT SMIT, Free University of Amsterdam
    There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like
    …
    Read more
    Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
    • in General Medicine
    • — 17 Mar, 2008

    Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors

    Silvia Novello
    Silvia Novello

    SILVIA NOVELLO, University of Turin
    Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs
    …
    Read more
  • ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
    • in Oncology
    • — 15 Dec, 2007

    ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

    Jack Cuzick
    Jack Cuzick

    JACK CUZICK, Wolfson Institute of Preventive Medicine, London
    New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data
    …
    Read more
    Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
    • in Oncology
    • — 16 Nov, 2007

    Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

    Jean-Yves Douillard
    Jean-Yves Douillard
    Gordon McVie
    Gordon McVie

    REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    JEAN-YVES DOUILLARD, Centre René Gauducheau, Nante
    COMMENT: GORDON MCVIE, European Institute of Oncology, Milan

    The vinca alkaloid vinflunine and
    …
    Read more
  • Eptifibatide After PCI: Brief Infusion Is Just As Good
    • in Cardiovascular
    • — 5 Nov, 2007

    Eptifibatide After PCI: Brief Infusion Is Just As Good

    Anthony Fung
    Anthony Fung
    REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    ANTHONY FUNG, University of British Columbia, Vancouver
    Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as
    …
    Read more
    KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer
    • in Oncology
    • — 31 Aug, 2007

    KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

    Pierre Laurent-Puig
    Pierre Laurent-Puig
    Bill Hait
    Bill Hait

    REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
    PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
    COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ

    The presence of the KRAS mutation in tumor
    …
    Read more
  • Virus Plus Cytokine Fight Primary and Metastatic Cancer
    • in Oncology
    • — 15 Aug, 2007

    Virus Plus Cytokine Fight Primary and Metastatic Cancer

    Paul Fisher
    Paul Fisher

    REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles
    PAUL FISHER, Columbia University, New York
    Patients with cancer could soon be treated with adenoviruses capable of infecting both primary and distant tumors, and simultaneously releasing cancer-fighting cytokines, according
    …
    Read more
    Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study
    • in Public Health
    • — 19 Jan, 2007

    Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study

    Rodger MacArthur

    RODGER MACARTHUR, Wayne State University, Detroit

    REFERENCE: Lancet 2006; 368: 2125-35
    A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs),
    …
    Read more
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: inhibitors

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.